Current issues in the management of endometrial cancer

Jamie N Bakkum-Gamez, Jesus Gonzalez-Bosquet, Nadia N Laack, Andrea Mariani, Sean Christopher Dowdy

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Endometrial cancer (EC) remains the most common gynecologic malignancy in the United States. It is expected to become more common as the prevalence of obesity, one of the most common risk factors for EC, increases worldwide. The 2 main histologic subcategories of EC, endometrioid and nonendometrioid EC, show unique molecular aberrations and are responsible for markedly disparate clinical behaviors. The primary treatment of EC is surgery, ie, hysterectomy, removal of the adnexa, and pelvic and para-aortic lymphadenectomy, either via laparotomy or endoscopic techniques. Adjuvant therapy is necessary for patients at high risk of recurrence and consists of vaginal brachytherapy, teletherapy, systemic chemotherapy, or some combination thereof. Multi-institutional trials are in progress in this country and in Europe to better define optimal adjuvant treatment for subsets of patients, as well as the role of surgical staging in reducing both overuse and underuse of radiation therapy. Hormonal therapy is an option for some young women with EC who wish to preserve fertility. This review summarizes the diagnosis and management of EC and discusses current controversies and upcoming investigations pertaining to EC staging and adjuvant treatment.

Original languageEnglish (US)
Pages (from-to)97-112
Number of pages16
JournalMayo Clinic Proceedings
Volume83
Issue number1
DOIs
StatePublished - 2008

Fingerprint

Endometrial Neoplasms
Therapeutics
Neoplasm Staging
Brachytherapy
Lymph Node Excision
Hysterectomy
Laparotomy
Fertility
Radiotherapy
Obesity
Recurrence
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Current issues in the management of endometrial cancer. / Bakkum-Gamez, Jamie N; Gonzalez-Bosquet, Jesus; Laack, Nadia N; Mariani, Andrea; Dowdy, Sean Christopher.

In: Mayo Clinic Proceedings, Vol. 83, No. 1, 2008, p. 97-112.

Research output: Contribution to journalArticle

@article{dd4b9096555143c69a4f26ac4640d85d,
title = "Current issues in the management of endometrial cancer",
abstract = "Endometrial cancer (EC) remains the most common gynecologic malignancy in the United States. It is expected to become more common as the prevalence of obesity, one of the most common risk factors for EC, increases worldwide. The 2 main histologic subcategories of EC, endometrioid and nonendometrioid EC, show unique molecular aberrations and are responsible for markedly disparate clinical behaviors. The primary treatment of EC is surgery, ie, hysterectomy, removal of the adnexa, and pelvic and para-aortic lymphadenectomy, either via laparotomy or endoscopic techniques. Adjuvant therapy is necessary for patients at high risk of recurrence and consists of vaginal brachytherapy, teletherapy, systemic chemotherapy, or some combination thereof. Multi-institutional trials are in progress in this country and in Europe to better define optimal adjuvant treatment for subsets of patients, as well as the role of surgical staging in reducing both overuse and underuse of radiation therapy. Hormonal therapy is an option for some young women with EC who wish to preserve fertility. This review summarizes the diagnosis and management of EC and discusses current controversies and upcoming investigations pertaining to EC staging and adjuvant treatment.",
author = "Bakkum-Gamez, {Jamie N} and Jesus Gonzalez-Bosquet and Laack, {Nadia N} and Andrea Mariani and Dowdy, {Sean Christopher}",
year = "2008",
doi = "10.4065/83.1.97",
language = "English (US)",
volume = "83",
pages = "97--112",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "1",

}

TY - JOUR

T1 - Current issues in the management of endometrial cancer

AU - Bakkum-Gamez, Jamie N

AU - Gonzalez-Bosquet, Jesus

AU - Laack, Nadia N

AU - Mariani, Andrea

AU - Dowdy, Sean Christopher

PY - 2008

Y1 - 2008

N2 - Endometrial cancer (EC) remains the most common gynecologic malignancy in the United States. It is expected to become more common as the prevalence of obesity, one of the most common risk factors for EC, increases worldwide. The 2 main histologic subcategories of EC, endometrioid and nonendometrioid EC, show unique molecular aberrations and are responsible for markedly disparate clinical behaviors. The primary treatment of EC is surgery, ie, hysterectomy, removal of the adnexa, and pelvic and para-aortic lymphadenectomy, either via laparotomy or endoscopic techniques. Adjuvant therapy is necessary for patients at high risk of recurrence and consists of vaginal brachytherapy, teletherapy, systemic chemotherapy, or some combination thereof. Multi-institutional trials are in progress in this country and in Europe to better define optimal adjuvant treatment for subsets of patients, as well as the role of surgical staging in reducing both overuse and underuse of radiation therapy. Hormonal therapy is an option for some young women with EC who wish to preserve fertility. This review summarizes the diagnosis and management of EC and discusses current controversies and upcoming investigations pertaining to EC staging and adjuvant treatment.

AB - Endometrial cancer (EC) remains the most common gynecologic malignancy in the United States. It is expected to become more common as the prevalence of obesity, one of the most common risk factors for EC, increases worldwide. The 2 main histologic subcategories of EC, endometrioid and nonendometrioid EC, show unique molecular aberrations and are responsible for markedly disparate clinical behaviors. The primary treatment of EC is surgery, ie, hysterectomy, removal of the adnexa, and pelvic and para-aortic lymphadenectomy, either via laparotomy or endoscopic techniques. Adjuvant therapy is necessary for patients at high risk of recurrence and consists of vaginal brachytherapy, teletherapy, systemic chemotherapy, or some combination thereof. Multi-institutional trials are in progress in this country and in Europe to better define optimal adjuvant treatment for subsets of patients, as well as the role of surgical staging in reducing both overuse and underuse of radiation therapy. Hormonal therapy is an option for some young women with EC who wish to preserve fertility. This review summarizes the diagnosis and management of EC and discusses current controversies and upcoming investigations pertaining to EC staging and adjuvant treatment.

UR - http://www.scopus.com/inward/record.url?scp=37549061012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549061012&partnerID=8YFLogxK

U2 - 10.4065/83.1.97

DO - 10.4065/83.1.97

M3 - Article

C2 - 18174012

AN - SCOPUS:37549061012

VL - 83

SP - 97

EP - 112

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 1

ER -